
Full INTerpath-001 results show the individualized mRNA therapy plus pembrolizumab reduced recurrence risk in resected stage IIB-IV melanoma.
Supplements and Featured Publications
This publication highlights key strategies used by M Health Fairview to implement successful adoption of biosimilars.






